Meanwhile, the BSE Sensex was up 107.87 points or 0.55% at 19,771.42.
On BSE, 22,000 shares were traded in the counter as against average daily volume of 75,523 shares in the past one quarter.
The stock hit a high of Rs 592 and a low of Rs 584.45 so far during the day. The stock had hit a record high of Rs 631.90 on 10 September 2012. The stock had hit a 52-week low of Rs 412.15 on 9 February 2012.
The stock had underperformed the market over the past one month till 10 January 2013, declining 3.05% compared with the Sensex's 1.31% rise. The scrip had also underperformed the market in past one quarter, gaining 3.15% as against Sensex's 5.54% surge.
The large-cap company has equity capital of Rs 89.48 crore. Face value per share is Rs 2.
Shares of Lupin had declined 4.75% in seven trading sessions to settle at Rs 585.30 on Thursday, 10 January 2013, from a recent high of Rs 614.50 on 1 January 2013.
Lupin's consolidated net profit rose 8.8% to Rs 290.46 crore on 28.6% growth in net sales to Rs 2239.26 crore in Q2 September 2012 over Q2 September 2011.
Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The company has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.
Powered by Capital Market - Live News
